ArticleNeuropsychiatric disease and treatment2024
Clinical Insights into Neurosyphilis Patients with Leptomeningeal Enhancement of Spinal Cord.
Article in Neuropsychiatric disease and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tabes Dorsalis With Spinal Meningeal Involvement and Possible Concomitant Epstein-Barr Virus Reactivation.Cureus · 2026Article
- Case Report: Neurosyphilis with a paraparetic Guillain-Barré-spectrum phenotype and CSF-detected anti-GT1a IgG: an infection-autoimmunity diagnostic challenge.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: This study aims to report the clinical, biological, and imaging features of cross-sectional study of neurosyphilis patients with leptomeningeal enhancement of spinal cord. Here, 51 neurosyphilis patients with leptomeningeal enhancement of spinal cord positivity are described, offering a promise in terms of early diagnosis, thereby enabling timely detection and treatment. Methods: We retrospectively included all neurosyphilis patients enrolled in this study from December 2019 to January 2024. We identified 51 included patients with leptomeningeal enhancement of spinal cord positivity. Their neuroimaging, socio-demographical, clinical status, presentations, and laboratory manifestations were reported retrospectively. Results: Magnetic resonance imaging showed lumbar or conus medullaris and cauda equina radial enhancement in 72.7%, leptomeningeal enhancement of cervical spine in 65.9%, and thoracic involvement in 55.3%. Twenty of 51 neurosyphilis patients completed the follow-up. Among the 20 patients, the lesioned region in half of patients was decreased or disappeared after therapy. The predominant phenotype was tabes dorsalis. Median age at onset was 51 years, and 72.5% were male. Urinary incontinence was found in 33.3% of patients, and memory deterioration in 39.2%. The most frequent physical sign was Argyll Robertson pupil (45.1%). The levels of white blood cells (25/28, 89.3%) and protein concentration (23/28, 82.9%) of cerebrospinal fluid were reduced in more patients after therapy. Conclusion: In this study, we first concurrently investigated the clinical course and the biological and imaging features of leptomeningeal enhancement of spinal cord. Leptomeningeal enhancement of spinal cord is common with neurosyphilis. Our findings can be useful for raising clinical awareness to select patients with symptoms of myelopathy in whom MRI images should be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.